JP5592890B2 - ピロロトリアジンキナーゼ阻害剤 - Google Patents

ピロロトリアジンキナーゼ阻害剤 Download PDF

Info

Publication number: JP5592890B2
Authority: JP; Japan
Prior art keywords: substituted; methyl; pyrazol; piperazinyl; pyrrolo
Prior art date: 2008-10-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2011531165A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012505234A (ja

JP2012505234A5 (2

Inventor

アショク・ブイ・プランデア

デイビッド・ビー・フレンネソン

ムソニ・ジー・カマウ

ラルグディ・エス・ハリクリシュナン

マーク・ジー・ソールニアー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-08

Filing date

2009-10-08

Publication date

2014-09-17

2009-10-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-03-01 Publication of JP2012505234A publication Critical patent/JP2012505234A/ja

2012-11-08 Publication of JP2012505234A5 publication Critical patent/JP2012505234A5/ja

2014-09-17 Application granted granted Critical

2014-09-17 Publication of JP5592890B2 publication Critical patent/JP5592890B2/ja

Status Expired - Fee Related legal-status Critical Current

2029-10-08 Anticipated expiration legal-status Critical

Links

VKZGTORDNRVMIN-UHFFFAOYSA-N CC(C)C(CC#N)=O Chemical compound CC(C)C(CC#N)=O VKZGTORDNRVMIN-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2011531165A 2008-10-08 2009-10-08 ピロロトリアジンキナーゼ阻害剤 Expired - Fee Related JP5592890B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10362008P	2008-10-08	2008-10-08
US61/103,620		2008-10-08
PCT/US2009/059945 WO2010042684A1 (en)	2008-10-08	2009-10-08	Pyrrolotriazine kinase inhibitors

Publications (3)

Publication Number	Publication Date
JP2012505234A JP2012505234A (ja)	2012-03-01
JP2012505234A5 JP2012505234A5 (2)	2012-11-08
JP5592890B2 true JP5592890B2 (ja)	2014-09-17

Family

ID=41664941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2011531165A Expired - Fee Related JP5592890B2 (ja)	2008-10-08	2009-10-08	ピロロトリアジンキナーゼ阻害剤

Country Status (5)

Country	Link
US (1)	US8445676B2 (2)
EP (1)	EP2344504B1 (2)
JP (1)	JP5592890B2 (2)
CN (1)	CN102245610B (2)
WO (1)	WO2010042684A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011513419A (ja) *	2008-03-06	2011-04-28	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
CN102675323B (zh) *	2012-06-01	2014-04-09	南京药石药物研发有限公司	吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
US9050345B2 (en) *	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
CN104016983B (zh) *	2013-10-08	2018-11-02	上海创诺制药有限公司	吡咯并三嗪类衍生物及其制法和用途
WO2015051500A1 (zh) *	2013-10-08	2015-04-16	上海创诺制药有限公司	吡咯并三嗪类衍生物及其制法和用途
SG11201604940VA (en) *	2013-12-17	2016-07-28	Merck Patent Gmbh	N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN104974163B (zh) *	2014-04-14	2017-11-07	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
WO2017070135A1 (en) *	2015-10-20	2017-04-27	Bristol-Myers Squibb Company	Prodrugs of 2-(4-(3-((4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperaz in-1-yl)propanamide derivatives as ck2 inhibitors for the treatment of cancer
RS61991B1 (sr) *	2016-07-14	2021-07-30	Lilly Co Eli	Derivati pirazolilaminobenzimidazola kao jak inhibitori
WO2021257857A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) *	2020-06-19	2021-12-23	Incyte Corporation	Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it)	2020-07-02	2025-09-12	Incyte Corp	Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en)	2020-12-21	2022-06-30	Incyte Corporation	Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es)	2021-02-25	2023-07-05	Incyte Corp	Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh)	2022-03-17	2024-12-20	因赛特公司	作为jak2 v617f抑制剂的三环脲化合物
AU2023249795A1 (en)	2022-04-08	2024-10-17	Shy Therapeutics, Llc	Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60026297T2 (de) *	1999-05-21	2006-11-02	Bristol-Myers Squibb Co.	Pyrrolotriazin kinasehemmer
BRPI0407282A (pt) *	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
CN100577663C (zh) *	2004-06-28	2010-01-06	布里斯托尔-迈尔斯·斯奎布公司	稠合杂环型激酶抑制剂
ATE479687T1 (de) *	2004-10-15	2010-09-15	Takeda Pharmaceutical	Kinaseinhibitoren
US7442700B2 (en) *	2005-07-01	2008-10-28	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko) *	2005-12-02	2014-11-19	바이엘 헬스케어 엘엘씨	과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
HRP20140688T1 (hr) *	2006-07-07	2014-10-24	Bristol-Myers Squibb Company	Inhibitori piroltriazin kinaze
US7531539B2 (en) *	2006-08-09	2009-05-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7982033B2 (en) *	2006-11-03	2011-07-19	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CN101687874B (zh) *	2007-04-18	2013-01-30	百时美施贵宝公司	吡咯并三嗪激酶抑制剂
CA2700489A1 (en) *	2007-09-25	2009-04-02	Bayer Healthcare Llc	Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
JP2011513419A (ja) *	2008-03-06	2011-04-28	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤

2009
- 2009-10-08 US US13/123,305 patent/US8445676B2/en active Active
- 2009-10-08 EP EP09793354.3A patent/EP2344504B1/en not_active Not-in-force
- 2009-10-08 WO PCT/US2009/059945 patent/WO2010042684A1/en not_active Ceased
- 2009-10-08 CN CN200980149134.7A patent/CN102245610B/zh not_active Expired - Fee Related
- 2009-10-08 JP JP2011531165A patent/JP5592890B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2010042684A4 (en)	2010-07-08
EP2344504A1 (en)	2011-07-20
WO2010042684A1 (en)	2010-04-15
JP2012505234A (ja)	2012-03-01
EP2344504B1 (en)	2014-06-04
CN102245610A (zh)	2011-11-16
US20110294816A1 (en)	2011-12-01
CN102245610B (zh)	2014-04-30
US8445676B2 (en)	2013-05-21

Legal Events

Date	Code	Title	Description
2012-09-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120921
2012-09-22	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120921
2014-03-19	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140318
2014-06-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140605
2014-07-04	TRDD	Decision of grant or rejection written
2014-07-09	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140708
2014-08-07	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140801
2014-08-08	R150	Certificate of patent or registration of utility model	Ref document number: 5592890 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2017-08-08	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5592890B2 (ja)	2014-09-17	ピロロトリアジンキナーゼ阻害剤
KR101392678B1 (ko)	2014-05-07	피롤로트리아진 키나제 억제제
KR101828187B1 (ko)	2018-02-09	신규 축합 피리미딘 화합물 또는 그 염
US9956220B2 (en)	2018-05-01	Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
JP6267231B2 (ja)	2018-01-24	カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP5180967B2 (ja)	2013-04-10	ピロロトリアジンキナーゼ阻害剤
CN104837844B (zh)	2017-08-29	作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
EP2049542A1 (en)	2009-04-22	Pyrrolotriazine kinase inhibitors
EP3071571A1 (en)	2016-09-28	Pyrrolopyrrolone derivatives and their use as bet inhibitors
TWI797711B (zh)	2023-04-01	一種fgfr及其突變抑制劑，其製備方法和應用
TW202128646A (zh)	2021-08-01	氰基取代吡啶及氰基取代嘧啶類化合物、製備方法及其應用
CN108484606B (zh)	2020-03-06	一种嘧啶并[4,5-f]喹唑啉类化合物及其应用